Skip to main content

Advertisement

Table 4 Survival times and progression times between cTACE and DEB-TACE treatments for patients with tumor number > 5 or sum of the diameter of the largest five HCC tumors was > 7 cm

From: Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

Variables cTACE DEB-TACE p-value
(n = 78) (n = 33)
Survival status    0.610
 Died within ≤5 years follow-up 62 (79.5) 26 (78.8)  
 Died after more than 5 years follow-up 3 (3.8) 0 (0)  
 Survived until last follow-up 13 (16.7) 7 (21.2)  
Progression status    0.360
 Progression 75 (96.2) 30 (90.9)  
 Loss of follow-up/censored 3 (3.8) 3 (9.1)  
Survival time, months 31 (26.7, 35.3) 27 (22.3, 31.7) 0.789
Progression time, months 9 (6.7, 11.3) 12 (8.0, 16.0) 0.492
  1. Survival and progression status are summarized as n (%) by treatment; Survival time- and progression time-related data are summarized as median (95%CI) by treatment
  2. Differences between treatments were compared using Pearson Chi-square test / or Fisher’s exact test for survival and progression status and Log-rank test for survival time or progression time